产品
编 号：F744701
分子式：C87H95Cl3N16O28S2
分子量：1983.26
分子式：C87H95Cl3N16O28S2
分子量：1983.26
产品类型
规格
价格
是否有货
结构图
CAS No: 1393900-12-3
产品详情
生物活性：
Cefilavancin (TD-1792) is a potent multivalent glycopeptide-cephalosporin heterodimer antibiotic with effective activity against Gram-positive bacteria. Cefilavancin has been used to research skin infections.
体内研究：
Cefilavancin (0.03-10 mg/kg; s.c.) produces a dose-dependent reduction of thigh bacterial burden in infected mice.Animal Model:Female NSA mice (18-30 g; neutropenia induced by administering cyclophosphamide, then injected bacteria into the posterior thigh)
Dosage:0.03-10 mg/kg
Administration:s.c.; single dosage (every 24 h) or two (every 12 h), three (every 8 h), or four (every 6 h) divided doses
Result:Produced a maximal of approximately 1- to 2-log10 kill against MRSA ATCC 33591, MSSA ATCC 29213, and MRSE MED 820 and ≥3-log10 kill against VISA HIP 5836, MSSE SU03, PSSP MED35, PSSP MED1119, and Streptococcus pyogenes MED 2040 strains.
体外研究：
Cefilavancin (TD-1792) has highly active against Methicillin-susceptible Staphylococcus aureus (MIC90 = 15 ng/mL), Methicillin-resistant Staphylococcus aureus, and heterogeneous Vancomycin-intermediate Staphylococcus aureus (MIC90 = 30 ng/mL).
Cefilavancin (TD-1792) is a potent multivalent glycopeptide-cephalosporin heterodimer antibiotic with effective activity against Gram-positive bacteria. Cefilavancin has been used to research skin infections.
体内研究：
Cefilavancin (0.03-10 mg/kg; s.c.) produces a dose-dependent reduction of thigh bacterial burden in infected mice.Animal Model:Female NSA mice (18-30 g; neutropenia induced by administering cyclophosphamide, then injected bacteria into the posterior thigh)
Dosage:0.03-10 mg/kg
Administration:s.c.; single dosage (every 24 h) or two (every 12 h), three (every 8 h), or four (every 6 h) divided doses
Result:Produced a maximal of approximately 1- to 2-log10 kill against MRSA ATCC 33591, MSSA ATCC 29213, and MRSE MED 820 and ≥3-log10 kill against VISA HIP 5836, MSSE SU03, PSSP MED35, PSSP MED1119, and Streptococcus pyogenes MED 2040 strains.
体外研究：
Cefilavancin (TD-1792) has highly active against Methicillin-susceptible Staphylococcus aureus (MIC90 = 15 ng/mL), Methicillin-resistant Staphylococcus aureus, and heterogeneous Vancomycin-intermediate Staphylococcus aureus (MIC90 = 30 ng/mL).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备